http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2253461-C1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2004-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84e3139414db8154625fe34f5796152a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c8af2e7eb4fd55cc97562780cf940ba |
| publicationDate | 2005-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2253461-C1 |
| titleOfInvention | Pharmaceutical combination influencing central nervous system function; method of correcting conditions associated with dysfunction of central nervous system; pharmaceutical kit; agent assisting therapeutical substances and metabolites to cross blood-brain barrier; and endonasal drug |
| abstract | FIELD: pharmacology. n SUBSTANCE: invention provides a pharmaceutical combination influencing central nervous system function, which contains (i) at least one compound influencing central nervous system function; (ii) at least one compound beneficially affecting central nervous system, and compound assisting first compound to cross blood-brain barrier, namely an agent for endonasal administration manifesting reflex, preferably neuro- and vasoactive action on nasal mucosa structures and receptors, basically receptors of vomeronasal organ and trigeminal nerve systems; (iii) active oxygen forms selected from hydrogen superoxide, hydrogen peroxide, NO - , and CO-active compounds; and (iv) pharmacological stabilizer. n EFFECT: lowered doses and reduced adverse effects. n 22 cl, 2 tbl, 8 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013167112-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2624232-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2566713-C1 |
| priorityDate | 2004-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.